Article
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Cancer - 1 Apr 2011
Ilson David H, Kelsen David, Shah Manish, Schwartz Gary, Levine Douglas A, Boyd Jeff, Capanu Marinela, Miron Benjamin, Klimstra David
Abstract excerpt
BACKGROUND: Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer. METHODS: Thirty patients with measurable, metastatic cancer of the esophageal and gastroesophageal junction received 150 mg erlotinib daily. EGFR-negative tumors (6 patients; 20%) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.